rs1800797
|
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Among postmenopausal women not recently exposed to hormones, the AG/GG genotypes of rs1800797 (-596A>G) and the GC/CC genotypes of rs1800795 (-174G>C) significantly reduced risk of breast cancer among non-Hispanic white women [odds ratio (OR), 0.69; 95% confidence interval (95% CI), 0.48-1.00 and OR, 0.68; 95% CI, 0.47-0.99, respectively] and Hispanic/Native American women (OR, 0.48; 95% CI, 0.28-0.83 and OR, 0.44; 95% CI, 0.26-0.99, respectively).
|
17416766 |
2007 |
rs1800795
|
|
Malignant neoplasm of breast
|
|
0.060 |
GeneticVariation
|
BEFREE |
Among postmenopausal women not recently exposed to hormones, the AG/GG genotypes of rs1800797 (-596A>G) and the GC/CC genotypes of rs1800795 (-174G>C) significantly reduced risk of breast cancer among non-Hispanic white women [odds ratio (OR), 0.69; 95% confidence interval (95% CI), 0.48-1.00 and OR, 0.68; 95% CI, 0.47-0.99, respectively] and Hispanic/Native American women (OR, 0.48; 95% CI, 0.28-0.83 and OR, 0.44; 95% CI, 0.26-0.99, respectively).
|
17416766 |
2007 |
rs1800795
|
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Among postmenopausal women not recently exposed to hormones, the AG/GG genotypes of rs1800797 (-596A>G) and the GC/CC genotypes of rs1800795 (-174G>C) significantly reduced risk of breast cancer among non-Hispanic white women [odds ratio (OR), 0.69; 95% confidence interval (95% CI), 0.48-1.00 and OR, 0.68; 95% CI, 0.47-0.99, respectively] and Hispanic/Native American women (OR, 0.48; 95% CI, 0.28-0.83 and OR, 0.44; 95% CI, 0.26-0.99, respectively).
|
17416766 |
2007 |
rs1800795
|
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Among women without recent hormone exposure, those with a WHR >0.9 and the rs1800795 GG genotype had a greater than threefold increased risk of bre</span>ast cancer (odds ratios (ORs) 3.22, 95% confidence intervals (CIs) 1.27, 817) when compared with women with a WHR <0.8 and the rs1800795 GG genotype (P interaction 0.01).
|
18239642 |
2008 |
rs1800795
|
|
Malignant neoplasm of breast
|
|
0.060 |
GeneticVariation
|
BEFREE |
Among women without recent hormone exposure, those with a WHR >0.9 and the rs1800795 GG genotype had a greater than threefold increased risk of bre</span>ast cancer (odds ratios (ORs) 3.22, 95% confidence intervals (CIs) 1.27, 817) when compared with women with a WHR <0.8 and the rs1800795 GG genotype (P interaction 0.01).
|
18239642 |
2008 |
rs1800795
|
|
Diabetes Mellitus, Non-Insulin-Dependent
|
|
0.070 |
GeneticVariation
|
BEFREE |
An association of the rs1800795 SNP of the IL-6 gene with T2D has been detected for the first time in Cretans.
|
29957071 |
2018 |
rs1800795
|
|
Cervix carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Association of <i>IL-6</i> -174G>C (rs1800795) polymorphism with cervical cancer susceptibility.
|
30135142 |
2018 |
rs1800795
|
|
Malignant tumor of cervix
|
|
0.040 |
GeneticVariation
|
BEFREE |
Association of <i>IL-6</i> -174G>C (rs1800795) polymorphism with cervical cancer susceptibility.
|
30135142 |
2018 |
rs1800795
|
|
cervical cancer
|
|
0.040 |
GeneticVariation
|
BEFREE |
Association of <i>IL-6</i> -174G>C (rs1800795) polymorphism with cervical cancer susceptibility.
|
30135142 |
2018 |
rs1800796
|
|
Chorioamnionitis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Association of a placental Interleukin-6 genetic variant (rs1800796) with DNA methylation, gene expression and risk of acute chorioamnionitis.
|
30795743 |
2019 |
rs1800796
|
|
Degenerative polyarthritis
|
|
0.020 |
GeneticVariation
|
BEFREE |
Association of interleukin-6 gene polymorphism (rs1800796) with severity and functional status of osteoarthritis in elderly individuals.
|
26233477 |
2015 |
rs2069837
|
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Associations between potentially functional IL6 (rs2069837 and rs1800795) and STAT3 (rs744166 and rs4796793) SNPs and clinical outcomes [progression-free survival (PFS), overall survival, and tumor response rate] were evaluated in mCRC patients receiving first-line FOLFIRI plus bevacizumab in two randomized phase III trials: TRIBE (n = 223, training cohort) and FIRE-3 (n = 288, validation cohort).
|
26839145 |
2016 |
rs1800795
|
|
Neoplasms
|
|
0.050 |
GeneticVariation
|
BEFREE |
Associations between potentially functional IL6 (rs2069837 and rs1800795) and STAT3 (rs744166 and rs4796793) SNPs and clinical outcomes [progression-free survival (PFS), overall survival, and tumor response rate] were evaluated in mCRC patients receiving first-line FOLFIRI plus bevacizumab in two randomized phase III trials: TRIBE (n = 223, training cohort) and FIRE-3 (n = 288, validation cohort).
|
26839145 |
2016 |
rs1800795
|
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.010 |
GeneticVariation
|
BEFREE |
Associations between potentially functional IL6 (rs2069837 and rs1800795) and STAT3 (rs744166 and rs4796793) SNPs and clinical outcomes [progression-free survival (PFS), overall survival, and tumor response rate] were evaluated in mCRC patients receiving first-line FOLFIRI plus bevacizumab in two randomized phase III trials: TRIBE (n = 223, training cohort) and FIRE-3 (n = 288, validation cohort).
|
26839145 |
2016 |
rs1800795
|
|
Anthracosilicosis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Associations of polymorphisms in the cytokine genes IL1β (rs16944), IL6 (rs1800795), IL12b (rs3212227) and growth factor VEGFA (rs2010963) with anthracosilicosis in coal miners in Russia and related genotoxic effects.
|
29378067 |
2018 |
rs1800795
|
|
Bacteremia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Associations were found between the CC genotype of IL6 SNP rs1800795 and occurrence of bacteremia and between TLR5 SNP rs5744168 and protection from UTI.
|
25807366 |
2015 |
rs1800795
|
|
Urinary tract infection
|
|
0.010 |
GeneticVariation
|
BEFREE |
Associations were found between the CC genotype of IL6 SNP rs1800795 and occurrence of bacteremia and between TLR5 SNP rs5744168 and protection from UTI.
|
25807366 |
2015 |
rs1800795
|
|
Childhood Neuroblastoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Because the rs1800795 SNP [-174 IL-6 (G > C)] has been shown to correlate with production of IL-6, this cytokine may represent a target for development of new therapies in neuroblastoma.
|
19671870 |
2009 |
rs1800795
|
|
Central neuroblastoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Because the rs1800795 SNP [-174 IL-6 (G > C)] has been shown to correlate with production of IL-6, this cytokine may represent a target for development of new therapies in neuroblastoma.
|
19671870 |
2009 |
rs1800795
|
|
Neuroblastoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Because the rs1800795 SNP [-174 IL-6 (G > C)] has been shown to correlate with production of IL-6, this cytokine may represent a target for development of new therapies in neuroblastoma.
|
19671870 |
2009 |
rs1800797
|
|
Hepatitis C
|
|
0.010 |
GeneticVariation
|
BEFREE |
Carriage of IL-6 rs1800796 G/G genotype, IL-6 rs1474358 C-allele, and IL-6 rs1800797 A-allele was more frequent in chronic HCV-infected patients than in HCC patients.
|
28340949 |
2017 |
rs1800797
|
|
Liver carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Carriage of IL-6 rs1800796 G/G genotype, IL-6 rs1474358 C-allele, and IL-6 rs1800797 A-allele was more frequent in chronic HCV-infected patients than in HCC patients.
|
28340949 |
2017 |
rs2066992
|
|
Coronary Artery Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
CC genotype and C allele in rs614230 (CX3CL1) were significantly related with decreased risk of CAD (OR=0.38, 95% CI=0.17-0.86; OR=0.66, 95% CI=0.45-0.97).For IL-6 rs2066992 polymorphism.
|
26191329 |
2015 |
rs1800795
|
|
Tuberculosis
|
|
0.040 |
GeneticVariation
|
BEFREE |
Collectively, this meta-analysis proved that IL-2 rs2069762, IL-4 rs2243250, IL-6 rs1800795, IL-8 rs4073, IL-10 rs1800871 and IL-10 rs1800896 polymorphisms may confer susceptibility to TB, especially for Asians.
|
31669382 |
2020 |
rs1800795
|
|
Tuberculosis
|
|
0.040 |
GeneticVariation
|
BEFREE |
Collectively, this meta-analysis proved that IL-6 rs1800795, IL-8 rs4073, IL-10 rs1800871, IL-10 rs1800872 and IL-10 rs1800896 may confer susceptibility to TB.
|
31560754 |
2019 |